BioWorld

Oct. 8, 2002

McClellan Breezes Through First Meeting Before Senate Committee

WASHINGTON - Nominee Mark McClellan easily jumped the first hurdle in becoming the next commissioner of the FDA from a largely absent Senate committee. (Bioworld Today) Read More

New Erbitux Trials Starting; ImClone Has Second Chance'

Phylogeny Test Opens Novel Path To Forensic Crime Detection, First In U.S.; Forecast As Future Model

Cell Therapeutics Starts NSCLC Phase III, Eyes One More In 2002

Quorex Enhances Platform By Acquiring Bioinformatics Firm

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

Ethyreal launches to treat the underlying cause of Graves’, TED

BioWorld

Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...

Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis

BioWorld

Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...

Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?

BioWorld

Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...

Microbiota modulates the antidepressant effects of GLP-1 analogues

BioWorld Science

Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...